KPV tripeptide reduces colitis severity and rescues mice from DSS-induced death
Background
Inflammatory bowel disease (IBD) remains difficult to treat, with persistently high surgery rates despite recent therapeutic advances. Alpha-melanocyte-stimulating hormone (alpha-MSH) and related melanocortin peptides have documented anti-inflammatory properties, including protective effects in dextran sodium sulfate (DSS) colitis in mice. The MC1R receptor (melanocortin-1 receptor) is one pathway through which melanocortins exert immune modulation, but its precise contribution to gut inflammation is incompletely understood. The C-terminal tripeptide fragment KPV (alpha-MSH residues 11–13) retains anti-inflammatory activity and represents a minimal, potentially more tractable therapeutic candidate. Whether KPV can recapitulate the broader anti-inflammatory effects of full-length alpha-MSH across mechanistically distinct colitis models — and whether its activity depends on MC1R signaling — had not been systematically evaluated.
Study Design
KPV (alpha-MSH[11-13]) was tested in two well-characterized murine IBD models: DSS-induced colitis and CD45RB(hi) T-cell transfer colitis. Disease course was tracked via body weight loss, histological scoring of colonic tissue, and myeloperoxidase (MPO) activity assays as a measure of neutrophil infiltration. To probe MC1R dependence, mice homozygous for a nonfunctional MC1R allele (MC1Re/e) were subjected to DSS colitis and treated with KPV alongside wild-type controls. Primary endpoints included survival, weight recovery, and histological inflammatory infiltrates.
Results
KPV treatment in the DSS-colitis model produced earlier recovery and a significantly stronger regain of body weight compared to untreated controls. Histological evaluation confirmed significantly reduced inflammatory infiltrates in the colonic tissue of KPV-treated animals. MPO activity — a direct index of neutrophil-driven tissue inflammation — was also significantly reduced in the colons of KPV-treated mice.
In
MC1Re/emice lacking functionalMC1Rsignaling, KPV treatment rescued all animals in the treatment group from death during DSS colitis — a striking survival benefit.
In the CD45RB(hi) transfer colitis model, KPV-treated animals again demonstrated recovery, body weight regain, and reduced histological inflammatory changes, replicating the DSS findings in an immunologically distinct colitis system. Taken together, the data indicate that KPV's anti-inflammatory effects operate through pathways that are at least partially independent of MC1R signaling, pointing to additional melanocortin receptor subtypes or receptor-independent mechanisms as contributors.
Key Findings
- KPV significantly reduced colonic inflammatory infiltrates and MPO activity in DSS colitis mice.
- KPV-treated mice showed earlier and significantly stronger body weight recovery vs. controls in DSS colitis.
- KPV rescued 100% of MC1Re/e mice (nonfunctional MC1R) from death during DSS colitis.
- Anti-inflammatory effects replicated in CD45RB(hi) T-cell transfer colitis model with weight regain and reduced histological changes.
- KPV effects appear at least partially independent of MC1R signaling.
Why It Matters
KPV's efficacy in two mechanistically distinct colitis models, including survival rescue in MC1R-null animals, meaningfully broadens its therapeutic relevance beyond a single signaling pathway — a common liability for melanocortin-targeted approaches. For clinicians and translational researchers, the MC1R-independent activity suggests KPV may retain benefit even in patient subpopulations with MC1R polymorphisms, which are common in fair-skinned individuals. The tripeptide structure of KPV is an asset for drug development, offering a small, chemically defined scaffold with potential for oral or local colonic delivery strategies. However, the gap between murine proof-of-concept and a validated clinical protocol is substantial — dose optimization, pharmacokinetics, and human inflammatory pathway translation remain open. Researchers and protocol designers should treat this as foundational mechanistic evidence rather than a dosing blueprint.
